| Primary |
| Influenza |
37.0% |
| Avian Influenza |
18.1% |
| H1n1 Influenza |
18.1% |
| Cough |
3.7% |
| Drug Use For Unknown Indication |
3.0% |
| Product Used For Unknown Indication |
2.7% |
| Sedation |
2.4% |
| Prophylaxis |
1.9% |
| Antiviral Prophylaxis |
1.6% |
| Nosocomial Infection |
1.6% |
| Antibiotic Therapy |
1.4% |
| Anti-infective Therapy |
1.3% |
| Pneumonia |
1.1% |
| Cerebral Palsy |
1.0% |
| Hypovolaemic Shock |
1.0% |
| Immunosuppression |
1.0% |
| Upper Gastrointestinal Haemorrhage |
1.0% |
| Wheezing |
1.0% |
| Hypotension |
0.8% |
| Acute Coronary Syndrome |
0.6% |
|
| Normal Newborn |
29.1% |
| Pregnancy |
14.1% |
| Pathogen Resistance |
8.4% |
| Acute Respiratory Distress Syndrome |
6.9% |
| Death |
5.7% |
| Pneumonia |
5.5% |
| Respiratory Failure |
5.0% |
| Drug Ineffective |
3.8% |
| Drug Exposure During Pregnancy |
3.6% |
| Thrombocytopenia |
2.4% |
| Delirium |
1.9% |
| Multi-organ Failure |
1.9% |
| Sepsis |
1.9% |
| Ventricular Septal Defect |
1.9% |
| Periproctitis |
1.4% |
| Septic Shock |
1.4% |
| Vomiting |
1.4% |
| Drug Resistance |
1.2% |
| Influenza |
1.2% |
| Premature Baby |
1.2% |
|
| Secondary |
| Product Used For Unknown Indication |
36.3% |
| Influenza |
10.9% |
| Drug Use For Unknown Indication |
10.7% |
| H1n1 Influenza |
8.4% |
| Prophylaxis |
4.6% |
| Immunosuppression |
4.5% |
| Avian Influenza |
4.0% |
| Foetal Exposure During Pregnancy |
3.3% |
| Pneumonia |
3.3% |
| Hypertension |
2.5% |
| Sedation |
2.2% |
| Cholecystitis Acute |
1.2% |
| Infection |
1.2% |
| Rheumatoid Arthritis |
1.2% |
| Mycobacterium Fortuitum Infection |
1.0% |
| Sepsis |
1.0% |
| Aspergillosis |
0.9% |
| Muscle Spasms |
0.9% |
| Prophylaxis Against Graft Versus Host Disease |
0.9% |
| Upper Gastrointestinal Haemorrhage |
0.9% |
|
| Pathogen Resistance |
12.8% |
| Drug Ineffective |
9.4% |
| Acute Respiratory Distress Syndrome |
7.7% |
| Death |
7.7% |
| Pneumonia |
7.7% |
| Vestibular Disorder |
6.8% |
| Multi-organ Failure |
6.0% |
| Respiratory Failure |
5.1% |
| Influenza |
4.3% |
| Torsade De Pointes |
4.3% |
| Foetal Distress Syndrome |
3.4% |
| Septic Shock |
3.4% |
| Shock |
3.4% |
| Hepatitis Cholestatic |
2.6% |
| Pregnancy |
2.6% |
| Renal Impairment |
2.6% |
| Sepsis |
2.6% |
| Serum Sickness |
2.6% |
| Thrombocytopenia |
2.6% |
| Toxicity To Various Agents |
2.6% |
|
| Concomitant |
| Drug Use For Unknown Indication |
27.1% |
| Product Used For Unknown Indication |
17.6% |
| Multiple Myeloma |
6.3% |
| Prophylaxis |
5.8% |
| H1n1 Influenza |
5.1% |
| Influenza |
4.9% |
| Hypertension |
3.7% |
| Immunosuppression |
3.0% |
| Infection |
3.0% |
| Adverse Event |
2.8% |
| Evidence Based Treatment |
2.8% |
| Mycobacterium Fortuitum Infection |
2.8% |
| Pneumonia |
2.6% |
| Atrial Fibrillation |
2.3% |
| Renal Failure Chronic |
2.1% |
| Constipation |
1.9% |
| Vasculitis |
1.9% |
| Antibiotic Therapy |
1.6% |
| Chronic Graft Versus Host Disease |
1.4% |
| Pain |
1.4% |
|
| Pneumonia |
9.3% |
| Respiratory Failure |
7.4% |
| Respiratory Tract Infection |
7.4% |
| Therapeutic Response Decreased |
7.4% |
| Death |
5.6% |
| Pyrexia |
5.6% |
| Sinus Arrest |
5.6% |
| Weight Decreased |
5.6% |
| Weight Increased |
5.6% |
| White Blood Cell Count Decreased |
5.6% |
| Drug Ineffective |
3.7% |
| H1n1 Influenza |
3.7% |
| Hallucination, Visual |
3.7% |
| Liver Injury |
3.7% |
| Multi-organ Failure |
3.7% |
| Neutropenia |
3.7% |
| Pancreatitis |
3.7% |
| Sepsis |
3.7% |
| Tachycardia |
3.7% |
| Abscess Fungal |
1.9% |
|
| Interacting |
| Atrial Fibrillation |
33.3% |
| Product Used For Unknown Indication |
14.3% |
| H1n1 Influenza |
9.5% |
| Hypertension |
9.5% |
| Influenza |
9.5% |
| Pyelonephritis |
9.5% |
| Cardiac Valve Disease |
4.8% |
| Deep Vein Thrombosis |
4.8% |
| Pulmonary Embolism |
4.8% |
|
| Drug Interaction |
25.0% |
| Torsade De Pointes |
25.0% |
| Haemoptysis |
16.7% |
| International Normalised Ratio Increased |
16.7% |
| Ascites |
8.3% |
| Vomiting |
8.3% |
|
